83 related articles for article (PubMed ID: 16685162)
1. [Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].
Hayakawa T; Sato M; Konaka M; Makino A; Hirohata T; Totsu S; Wada Y; Sato H; Inotsume N; Fujita A; Sekine K
Gan To Kagaku Ryoho; 2006 May; 33(5):633-8. PubMed ID: 16685162
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin-based chemotherapy: a randomized controlled trial.
Cheirsilpa A; Sinthusake T; Songsakkaesorn A; Visawaprasit S; Chulaka K; Changkuingdee N
Jpn J Clin Oncol; 2005 Dec; 35(12):695-9. PubMed ID: 16319109
[TBL] [Abstract][Full Text] [Related]
3. [A randomized crossover comparison of azasetron alone and azasetron plus dexamethasone for the prevention of nausea and vomiting by chemotherapy including cisplatin].
Fujii M; Kanke M; Arai Y; Kawai S; Enomoto H; Inaba H; Taguchi T; Tsukuda M
Gan To Kagaku Ryoho; 2000 Sep; 27(10):1557-63. PubMed ID: 11016001
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
5. Clinical comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea and anorexia.
Feng F; Zhang P; He Y; Li Y; Zhou M; Chen G; Li L
Chin Med Sci J; 2002 Sep; 17(3):168-72. PubMed ID: 12901541
[TBL] [Abstract][Full Text] [Related]
6. [A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin].
Tsukuda M; Mochimatsu I; Furukawa M; Kohno H; Kawai S; Enomoto H; Yago T; Matsuda H; Ikema Y; Zhou L
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1959-67. PubMed ID: 7487127
[TBL] [Abstract][Full Text] [Related]
7. [A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
Tanigaki Y; Mikami Y; Matsuda H; Horiuchi C; Taguchi T; Yoshida T; Ishitoya J; Katori H; Ikeda Y; Tsukuda M
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2091-5. PubMed ID: 16352934
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting.
Ho CL; Su WC; Hsieh RK; Lin ZZ; Chao TY
Jpn J Clin Oncol; 2010 Apr; 40(4):294-301. PubMed ID: 20026457
[TBL] [Abstract][Full Text] [Related]
9. Multicenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis.
Villalon A; Chan V
Support Care Cancer; 2004 Jan; 12(1):58-63. PubMed ID: 14655041
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of dexamethasone 8 mg and 16 mg for the prevention of acute and delayed cisplatin-induced emesis in patients with lung cancer].
Hayakawa T; Sato M; Hirohata T; Totsu S; Makino A; Wada Y; Sato H; Inotsume N; Fujita A; Sekine K
Yakugaku Zasshi; 2006 Jan; 126(1):61-6. PubMed ID: 16394651
[TBL] [Abstract][Full Text] [Related]
11. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial.
Tantipalakorn C; Srisomboon J; Thienthong H; Pantusart A; Suprasert P; Saereesongkhun C; Eamtang S; Sutthichat A; Pautad N
J Med Assoc Thai; 2004 Feb; 87(2):119-25. PubMed ID: 15061293
[TBL] [Abstract][Full Text] [Related]
12. [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in lung cancer patients on cisplatin].
Horichi N; Taguchi T; Furue H; Ikeda M; Tsukakoshi S
Gan To Kagaku Ryoho; 2001 Jul; 28(7):953-60. PubMed ID: 11478144
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint?
Koizumi W; Tanabe S; Nagaba S; Higuchi K; Nakayama N; Saigenji K; Nonaka M; Yago K
Chemotherapy; 2003 Dec; 49(6):316-23. PubMed ID: 14671433
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].
Okuyama K; Yoshimoto K; Iwase O; Ozeki T; Yamada Y
Yakugaku Zasshi; 2008 Apr; 128(4):649-55. PubMed ID: 18379183
[TBL] [Abstract][Full Text] [Related]
15. [Comparative Study of the Antiemetic Palonosetron for Lung Cancer Patients Treated with a Divided Dose of Cisplatin].
Umehara K; Wakamoto A; Hatsuyama T; Sato H; Kobayashi M; Fujita A; Sekine K
Gan To Kagaku Ryoho; 2016 Aug; 43(8):967-72. PubMed ID: 27539038
[TBL] [Abstract][Full Text] [Related]
16. [Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP].
Kimura E; Niimi S; Watanabe A; Akiyama M; Tanaka T
Gan To Kagaku Ryoho; 1996 Mar; 23(4):477-81. PubMed ID: 8678501
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Takenaka M; Okamoto Y; Ikeda K; Hashimoto R; Ueda T; Kurokawa N; Takagi T; Uejima E
Gan To Kagaku Ryoho; 2007 Mar; 34(3):403-7. PubMed ID: 17353632
[TBL] [Abstract][Full Text] [Related]
18. [Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP].
Kimura E; Niimi S; Watanabe A; Tanaka T
Gan To Kagaku Ryoho; 1997 May; 24(7):855-9. PubMed ID: 9170525
[TBL] [Abstract][Full Text] [Related]
19. Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron.
Kang YK; Park YH; Ryoo BY; Bang YJ; Cho KS; Shin DB; Kim HC; Lee KH; Park YS; Lee KS; Heo DS; Kim SY; Cho EK; Lim HY; Kim WK; Lee JA; Kim TY; Lee JC; Yoon HJ; Kim NK
J Int Med Res; 2002; 30(3):220-9. PubMed ID: 12166338
[TBL] [Abstract][Full Text] [Related]
20. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
